))
"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer
Manage episode 442326055 series 3560609
内容由Jacqueline Stone and Oncololgy News Central提供。所有播客内容（包括剧集、图形和播客描述）均由 Jacqueline Stone and Oncololgy News Central 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Figlin discusses how to navigate new options with Manali Bhave, MD, a breast medical oncologist and assistant professor at the Emory University School of Medicine in Atlanta. Dr. Bhave stresses that disease progression in breast cancer can’t be addressed with a one-size-fits- all option. “Where do we go from here? I think it is largely dependent on clinical factors, patient comorbidities, and even biomarker status,” she explains. Dr. Bhave and Dr. Figlin discuss recent developments in targeted therapies and important challenges. “We’ve come a long way in treating metastatic HR-positive, HER2-negative breast cancer as more of a chronic disease,” she says.
Dr. Bhave reported consulting fees from Lilly, Novartis, and AstraZeneca.
Dr. Figlin reported various financial relationships.
129集单集
分享
